GW6340 is a selective LXR agonist with potential anticancer activity that promotes macrophage reverse cholesterol transport (mRCT) and can be used to study atherosclerosis.
FY-21 is a selective LSD1 inhibitor (IC50= 340 nM) that inhibits proliferation and colony formation of leukemia cells, decreases mRNA levels of the transcription factors HOXA9 and MEIS1, and can be used in the study of leukemia.
JNK-IN-13 is a selective and potent JNK inhibitor that inhibits JNK3 and JNK2 and can be used in the study of diabetes, inflammation, and neurological disorders.
Antifungal agent 76 has broad-spectrum antifungal activity with a MIC value of 0.25-16 μg/mL.Antifungal agent 76 may act by disrupting fungal cell membranes and can be used to study fungal infections.
KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).
Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.
Tri-GalNAc(OAc)3 TFA, a triantenerrary N-acetylgalactosamine (tri-GalNAc) ligand, is utilized in the synthesis of GalNAc-lysosome-targeting chimera (GalNAc-LYTAC). This compound facilitates targeted protein degradation by engaging with the asialoglycoprotein receptor [1].
Tri-GalNAc-DBCO is a PIP-GalNAc coupling compound that binds ASGPR to drive protein down-regulation and target compounds for protein degradation via copper-free strain-promoted azide-alkyne cycloaddition coupled to azide on a non-specifically labeled antibody.
Nα,Nα-Bis(carboxymethyl)-L-lysine is a potent competitive inhibitor of bitter taste receptor 4, with an IC50 of 59 nM, and is utilized in studies related to bitter taste receptors [1] [2] [3].
